VEGFA and cancer: Because of the unique molecular profile, aggressive behavior of the cancer, and easy relapse in triple-negative patients, more clinical trials are developing and applying targeted drugs, such as epidermal growth factor receptor, vascular endothelial growth factor and poly (ADP-ribose) polymerase (PARP) inhibitors (Anders & Carey, 2008; Andre & Zielinski, 2012).